Search Results
49 items found for "Tian Jin"
- 📅 Dr. GPCR Summit 2022 is less than a month away!
GPCR Summit 2022 is less than a month away!
- Opioid Ligands Addressing Unconventional Binding Sites and More Than One Opioid Receptor Subtype
August 2022 "Opioid receptors (ORs) represent one of the most significant groups of G-protein coupled receptor (GPCR) drug targets and also act as prototypical models for GPCR function. In a constant effort to develop drugs with less side effects, and tools to explore the ORs nature and function, various (poly)pharmacological ligand design approaches have been performed. That is, besides classical ligands, a great number of bivalent ligands (i. e. aiming on two distinct OR subtypes), univalent heteromer-selective ligands and bitopic and allosteric ligands have been synthesized for the ORs. The scope of our review is to present the most important of the aforementioned ligands, highlight their properties and exhibit the current state-of-the-art pallet of promising drug candidates or useful molecular tools for the ORs." Read more at the source #DrGPCR #GPCR #IndustryNews
- Latrophilin-1 drives neuron morphogenesis and shapes chemo- and mechanosensation-dependent ...
neuron morphogenesis and shapes chemo- and mechanosensation-dependent behavior in C. elegans via a trans Caenorhabditis elegans can also function independently of their seven-transmembrane domain and C terminus (trans Here, we show that Latrophilin-1 acts in trans to mediate morphogenesis of sensory structures in the This trans function is physiologically relevant in copulation behavior.
- Cell Surface Calcium-Sensing Receptor Heterodimers: Mutant Gene Dosage Affects Ca 2+ Sensing but...
Finally, we observed that the Ca2+o -stimulated CaSR operated exclusively via signaling in-trans and not via combined in-trans and in-cis signaling.
- Nanobodies: New Dimensions in GPCR Signaling Research
References: Jin, B. K., Odongo, S., Radwanska, M., & Magez, S. (2023). M., Thian, F. S., Kobilka, T. S., Schnapp, A., Konetzki, I., Sunahara, R. K., Gellman, S.
- Gαs and Gαq/11 protein coupling bias of two AVPR2 mutants (R68W and V162A) that cause nephrogenic di
Recent studies showed that some AVPR2 mutations could cause biased Gαq/11 protein coupling rather than R68W showed bias to coupling with Gαq/11 protein rather than V162A and wild-type receptor.
- Learn about Dr. GPCR Ecosystem!
GPCR is much more than a podcast? Come check out the brand new Dr.
- Roles of Focal Adhesion Kinase PTK2 and Integrin αIIbβ3 Signaling in Collagen- and GPVI-Dependent...
The suppressive rather than activating effects of pGRP were confined to blood flow at a high shear rate Blockage of PTK2 or interference of CIB1 no more than slightly affected thrombus formation at a low shear
- Carola Weiss joins InterAx Biotech AG as VP Business Development
Carola Weiss is a Senior Executive with more than 20 years of international experience in the biopharmaceutical
- Illuminating the draggable GPCR-ome
This time with none other than Dr. Bryan Roth There are 10 open tickets available. Get yours now!
- Dr. Marta Filizola - Dr. GPCR Podcast
GPCR Podcast, we have none other than Dr. Marta Filizola!
- Dr. Juan José Fung - Dr. GPCR Podcast
Our guest is none other than Dr. Juan Jose Fung, Principal Scientist, at GPCR Therapeutics.
- X4 slashes pipeline, lays off staff just three weeks after netting a $55M PIPE
The move comes less than three weeks after X4 pulled together a $55 million PIPE and amended a loan facility
- Unconventional GPCR-PKA Communication in the Hedgehog Pathway
Our first guest speaker is none other than Dr. Ben Myers!
- Structural basis of GPCR coupling to distinct signal transducers: implications for biased signaling
determine partner preference; or (iii) the dynamics of GPCR binding to different types of partners rather than
- Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR with ...
Better known as GPCR, the fruitful research space has led to more than 700 approved drugs over previous
- Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief ...
Hassard is a commercial leader with more than three decades of experience leading sales and marketing
- Exploring pharmacological inhibition of G q/11 as an analgesic strategy
One potential solution is to develop analgesics that act at targets other than opioid receptors.
- Activation of the human chemokine receptor CX3CR1 regulated by cholesterol
A much smaller conformational change of helix VI upon activation than previously solved class A GPCR-Gi
- Nanobodies as Probes and Modulators of Cardiovascular G Protein-Coupled Receptors
In less than a decade, nanobodies, or recombinant single-domain antibody fragments from camelids, have
- Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer
Vraniak’s career spans more than 20 years of financial and commercial experience in the life sciences
- Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies
and anxiety, has shown, in the last decade, increasing evidence of its antitumoral properties in more than
- Targeted Therapies to Reduce Side Effects in Modern Drug Development
In fact, it is often costly, frustrating, and tortuous—and more often than not it ends in failure.
- Overview of adhesion GPCRs self-activation
each G protein with the receptor showed that there are more polar interactions in Gq/Gs engagements than Qian, Y., Ma, Z., Liu, C., Li, X., Zhu, X., Wang, N., Xu, Z., Xia, R., Liang, J., Duan, Y., Yin, H.,
- Structures of β 1-adrenergic receptor in complex with Gs and ligands of different efficacies
intermediate state complex comprising β1-AR and nucleotide-free Gs is more stable when binding a full agonist than
- Discovery of 3(2-aminoethyl)-thiazolidine-2,4-diones as a novel chemotype of sigma-1 receptor ligand
Six compounds showed more than 50% displacement of the radioligand at 10 µM concentration with compound
- GPCR Therapeutics welcomes Dr. Ed Brennan as their new Vice President, Head of Clinical Development
He has led teams that have filed more than 10 Investigational New Drug Applications (IND), as well as
- Bell-Evans model and steered molecular dynamics in uncovering the dissociation kinetics of ligands..
However, our predictions were many folds shorter than those determined experimentally.